Despite the severe adverse effects associated with Pradaxa, BI has continued to advertise and promote this drug to physicians to prescribe to patients. In fall 2012, BI commissioned a survey that was distributed to UK physicians. This survey asked physicians to compare Pradaxa to its competitors, warfarin, Xarelto, and a new anticoagulant. The doctors were paid US$105 upon completion of the survey. The problem with the survey is that it was heavily focused on the honorarium, in addition to offering physicians an extra £5 to doctors who indicated on the survey that their patients had switched between medicines. Furthermore, BI contracted an organization to conduct the survey and concerns surfaced that high research standards had not been maintained.
BI claims that this survey was part of a larger market research study and was not meant as a promotional strategy.
If You Switched Medicines, You Can Get a Little Extra
Lawsuit Information: Pradaxa
Pradaxa And Xarelto: Top Heart Doctors Concerned Over New Blood Thinners